592 related articles for article (PubMed ID: 33253920)
21. A Review on Remdesivir: A Broad-spectrum Antiviral Molecule for Possible COVID-19 Treatment.
Khazir J; Maqbool T; Mir BA
Mini Rev Med Chem; 2021; 21(17):2530-2543. PubMed ID: 33596800
[TBL] [Abstract][Full Text] [Related]
22. Antibodies to watch in 2021.
Kaplon H; Reichert JM
MAbs; 2021; 13(1):1860476. PubMed ID: 33459118
[TBL] [Abstract][Full Text] [Related]
23. US Food and Drug Administration (FDA) Emergency Use Authorization: Glass Half Full or Glass Half Empty?
Guharoy R; Krenzelok EP
Clin Infect Dis; 2021 Aug; 73(3):549-552. PubMed ID: 33104216
[TBL] [Abstract][Full Text] [Related]
24. The evidence base for emergency use authorizations for COVID-19 treatments: A rapid review.
Knowlson C; Byrne A; Wilkinson J; Whitmore C; Torgerson D
Health Sci Rep; 2023 Jan; 6(1):e1051. PubMed ID: 36644312
[TBL] [Abstract][Full Text] [Related]
25. Antiviral Drug Discovery for the Treatment of COVID-19 Infections.
Ng TI; Correia I; Seagal J; DeGoey DA; Schrimpf MR; Hardee DJ; Noey EL; Kati WM
Viruses; 2022 May; 14(5):. PubMed ID: 35632703
[TBL] [Abstract][Full Text] [Related]
26. COVID-19: A Review of Potential Treatments (Corticosteroids, Remdesivir, Tocilizumab, Bamlanivimab/Etesevimab, and Casirivimab/Imdevimab) and Pharmacological Considerations.
Nhean S; Varela ME; Nguyen YN; Juarez A; Huynh T; Udeh D; Tseng AL
J Pharm Pract; 2023 Apr; 36(2):407-417. PubMed ID: 34597525
[No Abstract] [Full Text] [Related]
27. Developing an Ethics Framework for Allocating Remdesivir in the COVID-19 Pandemic.
Lim S; DeBruin DA; Leider JP; Sederstrom N; Lynfield R; Baker JV; Kline S; Kesler S; Rizza S; Wu J; Sharp RR; Wolf SM
Mayo Clin Proc; 2020 Sep; 95(9):1946-1954. PubMed ID: 32861338
[TBL] [Abstract][Full Text] [Related]
28. An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19.
Singh AK; Singh A; Singh R; Misra A
Diabetes Metab Syndr; 2022 Feb; 16(2):102396. PubMed ID: 35051686
[TBL] [Abstract][Full Text] [Related]
29. Vaccine safety - is the SARS-CoV-2 vaccine any different?
Tau N; Yahav D; Shepshelovich D
Hum Vaccin Immunother; 2021 May; 17(5):1322-1325. PubMed ID: 33270474
[TBL] [Abstract][Full Text] [Related]
30. Compassionate Drug Use - Time Arising for a New Law in Bulgaria in the Era of COVID-19.
Dzhafer N; Papathanasiou JV
Folia Med (Plovdiv); 2020 Sep; 62(3):592-596. PubMed ID: 33009760
[TBL] [Abstract][Full Text] [Related]
31. Remdesivir and Hydroxychloroquine: A Compassionate Use in Covid-19.
Kaur A; Chaudhary G; Singh P; Arora S; Kaur R
Curr Drug Targets; 2021; 22(13):1536-1547. PubMed ID: 33371833
[TBL] [Abstract][Full Text] [Related]
32. US FDA erratic approach to placebo-controlled trials after issuing an emergency use authorization for a COVID-19 vaccine.
Dal-Ré R
Vaccine; 2021 Feb; 39(8):1180-1182. PubMed ID: 33516602
[No Abstract] [Full Text] [Related]
33. Potential Repurposed Therapeutics and New Vaccines against COVID-19 and Their Clinical Status.
Banday AH; Shameem SA; Ajaz SJ
SLAS Discov; 2020 Dec; 25(10):1097-1107. PubMed ID: 32692266
[TBL] [Abstract][Full Text] [Related]
34. Remdesivir against COVID-19 and Other Viral Diseases.
Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
[TBL] [Abstract][Full Text] [Related]
35. Assessment of adverse events associated with remdesivir use for coronavirus disease 2019 using real-world data.
Singh A; Kamath A
Expert Opin Drug Saf; 2021 Dec; 20(12):1559-1564. PubMed ID: 34328807
[No Abstract] [Full Text] [Related]
36. Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak.
Maciorowski D; Ogaugwu C; Durvasula SR; Durvasula R; Kunamneni A
SLAS Discov; 2021 Mar; 26(3):311-329. PubMed ID: 33319627
[TBL] [Abstract][Full Text] [Related]
37. COVID-19 vaccines: rapid development, implications, challenges and future prospects.
Kashte S; Gulbake A; El-Amin Iii SF; Gupta A
Hum Cell; 2021 May; 34(3):711-733. PubMed ID: 33677814
[TBL] [Abstract][Full Text] [Related]
38. Editorial: First Full Regulatory Approval of a COVID-19 Vaccine, the BNT162b2 Pfizer-BioNTech Vaccine, and the Real-World Implications for Public Health Policy.
Parums DV
Med Sci Monit; 2021 Sep; 27():e934625. PubMed ID: 34483336
[TBL] [Abstract][Full Text] [Related]
39. Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection.
Infante M; Ricordi C; Alejandro R; Caprio M; Fabbri A
Expert Rev Anti Infect Ther; 2021 Jan; 19(1):5-16. PubMed ID: 32693652
[TBL] [Abstract][Full Text] [Related]
40. BNT162b2 mRNA COVID-19 Vaccine: First Approval.
Lamb YN
Drugs; 2021 Mar; 81(4):495-501. PubMed ID: 33683637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
